focus -WSS

focus

author：fashion 2025-09-28 23:49:44 - browse：296

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Key House Republican on health care plans exit from Congress

hotspot

focus

WSS

Vaccine advisory panel ACIP left half staffed by HHS

A disappointing year of Humira biosimilars

Industry veterans launch new biotech VC with $310M

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Private equity deals in Medicare Advantage declines

Wikipedia

focus

hotspot

Apple is now the first public company to be valued at $3 trillion

White House announces new plan to address the growing threat of xylazine in overdose crisis

How to save PrEP access — and even expand it

Medicare threatens to cut off funding for HCA's Mission hospital

United colonoscopy coverage change 'may cost lives,' doctors say

White House announces new plan to address the growing threat of xylazine in overdose crisis

Peter Hotez and the public health issue of online harassment

See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo

Hepatitis C has a cure — but many Americans still lack access to it

ACA's risk program benefits Blue Cross Blue Shield insurers

knowledge

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

White House announces new plan to address the growing threat of xylazine in overdose crisis

Swim instructor mom warns parents not to buy blue swimsuits for kids

The U.S. needs a new definition of substance use “recovery”

Home health providers sue Medicare over payment cuts

For Medicare Advantage, Democrats want stronger protections around AI

hotspot

focus

hotspot

leisure time